Project Grant R21DE036472
- The National Institute of Dental and Craniofacial Research awarded the University of California, Los Angeles $410,706 on July 16, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to conduct genome-wide analysis of Fusobacterium nucleatum virulence mechanisms and their role in oral and systemic disease. The funded research identifies F. nucleatum virulence factors across the bacterial genome and characterizes the function of TetR-regulated ABC transporters in oxidative...
- The National Institute of Dental and Craniofacial Research awarded $234,000 to the University of Texas Health Science Center at Houston on September 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate decoy adhesion mechanisms by which the commensal bacterium Veillonella atypica shields oral epithelial cells from colonization and inflammatory damage by the pathogenic keystone species Porphyromonas gingivalis. The research dissects the molecular and...
- The National Institute of Dental and Craniofacial Research awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University $568,759 on May 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate microbial interactions and immune mechanisms in periodontitis. The research examines pathogen synergy between Fusobacterium nucleatum and Campylobacter rectus, two gram-negative anaerobes that consistently co-expand in periodontitis,...
- The National Institute of Dental and Craniofacial Research awarded Baylor College of Medicine $453,797 on June 5, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate the structures and functions of natural products in periodontal disease. The funded research centers on a novel biosynthetic gene cluster found in clinical isolates of Porphyromonas gingivalis that appears to encode an antibiotic selective for other P. gingivalis strains and related oral...
- The National Institute of Dental and Craniofacial Research awarded the Regents of the University of Michigan $583,620 on August 21, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to engineer transfer RNA-derived small RNAs (tsRNAs) as species-specific antimicrobial agents targeting oral pathobionts. The funded work develops chemically modified tsRNAs to suppress dental pathogens including Fusobacterium nucleatum, Porphyromonas gingivalis, and Treponema denticola while...
- The National Institute of Dental and Craniofacial Research (NIDCR), a component of the Department of Health and Human Services National Institutes of Health, awarded Loma Linda University $631,170 on July 21, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to conduct structural-functional studies of gingipain biogenesis and localization in the context of periodontitis and Porphyromonas gingivalis pathogenesis. The project will expand understanding of...
- The National Institute of Dental and Craniofacial Research awarded the University of Florida $574,966 on June 5, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate functional amyloid formation in Streptococcus mutans, the bacterium that causes dental caries. The research characterizes amyloid-forming proteins in S. mutans—including P1 (AGI/II), WAPA, CNM, and SMU_63—and examines how naturally occurring adhesin truncation products regulate biofilm...
- The National Institute of Dental and Craniofacial Research awarded the University of Massachusetts Lowell $100,676 on September 30, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to develop a three-dimensional in vitro human periodontal sulcus tissue model capable of reproducing healthy and disease states of gingivitis and periodontitis. The recipient will engineer a sustained tissue culture system that mimics key anatomical features of the gingival sulcus—including...
- The National Institute of Dental and Craniofacial Research awarded Loma Linda University $358,823 on September 11, 2025, under the Oral Diseases and Disorders Research program (CFDA 93.121) to conduct structural-functional studies of gingipain biogenesis and localization in periodontitis research. The research addresses therapeutic gaps in managing periodontitis, a chronic disease linked to systemic diseases including atherosclerosis, rheumatoid arthritis, cancers, diabetes, and Alzheimer's...
- The National Institute of Dental and Craniofacial Research, part of the Department of Health and Human Services National Institutes of Health, awarded the University of Florida $458,877 on August 1, 2026, through the Oral Diseases and Disorders Research program (CFDA 93.121) to develop an oral vaccine targeting Fusobacterium nucleatum in oral squamous cell carcinoma. The recipient will generate a recombinant Lactobacillus gasseri expressing B-cell linear epitopes of two F. nucleatum surface...
The National Institute of Dental and Craniofacial Research awarded the University of Texas Health Science Center at Houston $429,000 on July 16, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate how dietary composition influences Fusobacterium nucleatum physiology and virulence. The project will define the mechanism by which fruit peel extracts induce amyloid fibrils on F. nucleatum surfaces and re-examine the molecular model of amyloid genesis. The recipient will also elucidate the regulation and function of the GFRABCDEF operon in F. nucleatum subspecies nucleatum, including its role in Amadori product utilization and subspecies competition. Preliminary studies indicate that water extracts from apple, tomato, and grape peels—but not fruit flesh—activate this operon and trigger amyloidogenesis, while Amadori products selectively enrich certain F. nucleatum strains. The work aims to establish a mechanistic framework connecting diet, microbial amyloids, and subspecies-level ecology, with implications for understanding F. nucleatum's association with periodontitis, preterm birth, colorectal cancer, and Alzheimer's disease. Performance occurs in Houston, Texas, with a period of performance from July 16, 2026, through July 15, 2028. This is a Project Grant, classified as assistance funding under the NIDCR's extramural research program supporting basic, translational, and clinical research in dental, oral, and craniofacial health.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $429.0k | 7/20/26 |